Trisenox®
(Arsenic Trioxide)
| Manufacturer: Cephalon |
| General Information: Trisonex® is typically
utilized for the treatment of patients with acute promyelocytic
leukemia, characterized by the presence of t(15;17) translocation or
PML/RAR-alpha gene expression. |
| |
|
Product |
Size |
NDC Number |
PI |
MSDS |
| Trisenox® |
10mg-mL |
63459-0600-10 |
PI |
MSDS |
|
| |
| Clinical
Data: For any questions
or for further information
related to Trisenox®, clinical
pharmacology, additional
indications and usages,
contraindications, warnings,
precautions, adverse reactions,
dosage, administration and / or
storage of this product, please
contact
BDI Pharma or call 1-800-948-9834. |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |